Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PreCold is a fixed-dose combination pharmaceutical product marketed primarily in India for the symptomatic relief of the common cold and associated upper respiratory conditions. The medication integrates three active ingredients: paracetamol, phenylpropanolamine, and cetirizine. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, primarily within the central nervous system, to reduce pain and fever. Phenylpropanolamine is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-adrenergic receptors, leading to vasoconstriction of the nasal mucosa and reduction of swelling. Cetirizine is a second-generation antihistamine that provides relief from allergic symptoms such as sneezing, runny nose, and watery eyes by selectively antagonizing peripheral H1 receptors. Together, these components address the multi-symptom nature of viral respiratory infections and allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PreCold.